RecruitingNCT04377854

Prognostic Value of BNP in MCS - a 25 Year Follow up Study

The Prognostic Value of proBNP in Patients Supported With Durable Mechanical Circulatory Assist Devices - a 25 Year Follow up Study.

Sponsor

Rigshospitalet, Denmark

Enrollment

1,000 participants

Start Date

Sep 18, 2020

Study Type

OBSERVATIONAL

Conditions

Heart Failure Prognosis Left Ventricular Assist Device Durable Mechanical Support Device

Summary

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term follow-up study — not a treatment trial — that looks at whether a blood test called BNP (a marker of heart stress) can predict long-term outcomes in people with advanced heart failure who were evaluated for mechanical heart support or transplant. Researchers at a Danish hospital are reviewing 25 years of patient data. **You may be eligible if...** - You are 18 or older - You were referred to Rigshospitalet in Denmark for evaluation of advanced heart failure treatment **You may NOT be eligible if...** - You do not consent to participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation. No intervention per se.

Observation. No intervention (no collection of blood).

OTHER2) Observation and collection and of blood sample

All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.

Locations(1)

Rigshospitalet

Copenhagen, DK, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04377854

Related Trials

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

NCT054753667 locations

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288653 locations

Impact of Optimized Pacing Strategies on Clinical and Hemodynamic Outcomes in Heart Failure Patients With Pacemaker

NCT075631531 location

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370638 locations

HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

NCT074022391 location